NYSE$AGL
agilon health inc. · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
agilon health inc. reported its Q2 2025 financial results with a net loss of $104 million on lower membership and revenue.
Total revenues declined 6% year-over-year to $1.39 billion due to lower Medicare Advantage membership and unfavorable risk adjustment development. The company recorded a medical margin loss of $53 million and an Adjusted EBITDA loss of $83 million. Net loss attributable to common shares was $104 million, or $0.25 per share.
- Medicare Advantage membership fell 3% to 497,500 as of June 30, 2025 from partnership exits in 2024.
- Medical services revenue decreased 6% to $1.39 billion amid lower membership and higher Part D costs.
- Gross profit turned negative at $52 million loss versus $32 million profit in Q2 2024.
- Cash and cash equivalents stood at $171 million with continued negative operating cash flow of $67 million year-to-date.
Headline financials
Revenue & EPS history
agilon health · Revenue · Quarterly
$1.39B
Revenue by segment
agilon health · $1.39B total across 2 segments · Q2 2025
- Medical Services$1.39B—99.8%
- Other Operating$2.94M—0.2%
Forward guidance
No explicit forward guidance provided in the 10-Q filing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-2.6%
Avg return
Earnings day
-0.0%
Avg return
5 days after
+6.7%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+20.2%
Q4 2025
Best reaction
-36.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +4.2% | +122.0% | +256.9% | |
| Q4 2025 | +20.2% | +13.4% | -20.8% | |
| Q3 2025 | +5.1% | -9.0% | -9.9% | |
| Q1 2025 | -25.6% | -33.4% | -51.6% | |
| Q4 2024 | -7.4% | -17.9% | +23.7% | |
| Q3 2024 | -36.1% | -35.1% | -24.7% | |
| Q2 2024 | -12.7% | -14.6% | -36.8% | |
| Q1 2024 | +7.5% | +7.5% | +40.8% | |
| Q4 2023 | +3.1% | -2.1% | -1.1% | |
| Q3 2023 | -13.1% | -19.0% | -33.1% | |
| Q2 2023 | +0.7% | +3.7% | -7.9% | |
| Q1 2023 | -3.4% | -6.6% | -18.9% | |
| Q4 2022 | +15.4% | +14.8% | +12.0% | |
| Q3 2022 | -12.7% | -7.9% | -8.6% | |
| Q2 2022 | -3.3% | -0.4% | -20.3% | |
| Q1 2022 | -8.6% | -19.4% | +1.3% | |
| Q4 2021 | +10.6% | +2.4% | +31.7% | |
| Q3 2021 | +2.7% | +3.6% | -9.5% | |
| Q2 2021 | -3.8% | -6.3% | -3.4% | |
| Q1 2021 | +6.3% | +4.0% | +14.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro